These remain the first-line pharmacological treatments supported by robust clinical trial evidence and cost-effectiveness analyses
Human evidence - Phase 3 TRIUMPH-1 (Eli Lilly, May 21, 2026) 2,339 adults with obesity or overweight without diabetes
doi: 10.3390/biom13091332 Summary Keywords GLP-1 receptor agonists, Sepsis, muscle atrophy, inflammation, oxidative stress Citation Dimic N, Djuric M, Vejapi M, Nenadic I, Bobos M, Bojic S, Savic P, Milanovic M and Stevanovic P (2025) The role of GLP-1 in the pathophysiology and treatment of sepsis: a narrative review
The current weight-loss membership and medication are separate charges
Each weight loss program is customized for each patient based on various factors such as how much weight loss is desired, food preferences, current lifestyle, and other medical conditions